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Porphyrins are stable aromatic tetrapyrrolic macromolecules found in many
natural products such as hemin, chlorophylls and vitamin B12. Interaction ability of
cationic porphyrins with nucleic acid and their fluorescent properties for location
identification in cellular domain have promoted their uses as potential gene vectors
for gene therapy. In this study, basic cationic porphyrins bearing four positive
charges were synthesized. Besides, amphiphilic porphyrins anchored with both
hydrophobic and hydrophilic moieties were prepared to facilitate membrane
penetration and to give a higher cellular uptake. Polyamidoamine (PAMAM)-
porphyrin conjugate was also prepared to produce a complex with higher transfection
level but with low toxicity. Adler-Longo condensation method was mainly used to
synthesize these cationic porphyrin precursors. All cationic porphyrins were
obtained in high yield. All of the compounds were characterized using 1H-NMR,
13C-NMR, ultraviolet (UV) and infrared (IR) spectroscopies. Cytotoxicity and
cellular uptake of all cationic compounds were tested on Chinese Hamster Ovary
(CHO) cells to evaluate their potential uses as gene carriers. Results revealed that all
porphyrins show relatively low toxicity towards the cell even at high concentration
(100 µM). The 5,10,15,20-tetrakis(N-methyl-4-pyridyl)porphyrin and two
amphiphilic cationic porphyrins of 5-hexyl-10,15,20-tris(N-methyl-4-pyridyl)
porphyrin and 5-propyl-10,15,20-tris(N-methyl-4-pyridyl)porphyrin which contain
three positive charges on the periphery show the highest cellular uptake. It was also
found that the amphiphilic cis-porphyrins of 5,10-dipropyl-15,20-bis(N-methyl-4-
pyridyl)porphyrin and 5,10-dihexyl-15,20-bis(N-methyl-4-pyridyl)porphyrin






Porfirina adalah makromolekul aromatik yang stabil dan boleh dijumpai
dalam banyak sebatian semula jadi seperti hemin, klorofil dan vitamin B12.
Keupayaan porfirina kationik untuk berinteraksi dengan acid nukleik dan sifat
pendarfluor porfirina yang dapat menentukan lokasi vektor di dalam sel
menyebabkan ianya berpotensi untuk digunakan sebagai vektor gen bagi aplikasi
terapi gen. Dalam kajian ini, porfirina kationik asas yang mengandungi empat cas
positif telah disintesis. Selain itu, porfirina amfifilik yang bersifat hidrofobik dan
hidrofilik telah disediakan untuk memudahkan penetrasi membran dan meningkatkan
pengambilan bahan oleh sel. Konjugat poliamidoamina (PAMAM)-porfirina juga
disediakan untuk menghasilkan komplek yang mempunyai tahap transfeksi yang
lebih tinggi dengan ketoksikan yang rendah. Kaedah kondensasi Adler-Longo
digunakan untuk mensintesis pelbagai bahan mula porfirina kationik. Semua
porfirina kationik diperolehi dengan hasil yang tinggi. Semua sebatian telah
dicirikan dengan menggunakan spektroskopi 1H-RMN, 13C-RMN, ultralembayung
(UL) dan inframerah (IM). Kajian toksisiti dan pengambilan sel untuk semua
sebatian kationik tersebut dilakukan dengan menggunakan sel Ovari Hamster Cina
(CHO) untuk menilai potensinya sebagai pembawa gen. Keputusan kajian
mendapati bahawa semua porfirina menunjukkan ketoksikan yang agak rendah
walaupun pada kepekatan yang tinggi (100 µM). 5,10,15,20-Tetrakis(N-metil-4-
piridil)porfirina dan dua porfirina kationik amfifilik, 5-heksil-10,15,20-tris(N-metil-
4-piridil)porfirina dan 5-propil-10,15,20-tris(N-metil-4-piridil)porfirina yang
mengandungi tiga cas positif menunjukkan pengambilan selular yang tinggi.
Dapatan kajian juga menunjukkan cis-porfirina amfifilik, 5,10-dipropil-15,20-bis(N-
metil-4-pyridil)porfirina dan 5,10-diheksil-15,20-bis(N-metil-4-piridil)porfirina
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1.1 Background of the Study
Porphyrins (1) are important cofactor that can be found in massive amounts
of natural products such as chlorophyll (2) and hemin (3) [1]. They are the central
regulatory effectors in many biochemical processes. Over- or underproduction of
porphyrins will result in significant health problems ranging from mental illnesses

















Figure 1.1: Structure of porphyrin (1), chlorophyll (2) and hemin (3)
Porphyrins can be accessed through laboratory synthesis and they are
designed based on two porphyrins families; the β-substituted porphyrins that
resemble naturally occurring porphyrins and the meso-substituted porphyrins.
Porphyrins and their derivatives are usually synthesized based on condensation
reactions between pyrroles and aldehyde derivatives since it represents a facile and
straightforward synthetic method. Besides, different synthetic strategies also have




reaction (2+2 acid-catalysed condensation) [2], Vilsmeier reaction, nucleophilic
aromatic substitution reaction (SNAr reaction) [3], electrophilic substitution reaction
(SEAr reaction) [4] and transition-metal catalysed reactions [5].
Porphyrins which consist of large aromatic macrocyles possess important
chemical properties such as photochemical (energy and excitation transfer), redox
(electron transfer, catalysis) [6] and coordination properties (metal and axial ligand
binding) [7] which make these tetrapyrrole macrocyles play a crucial role in
disparate areas like photodynamic cancer therapy [8-9], artificial photosynthesis [10],
oxidation catalyst, sensors [11] and nanomaterial [12].
In addition, porphyrins and porphyrin-related macrocycles are found to have
ability to bind to lysosomes, mitochondria and plasma membrane [8]. Cationic
porphyrins have been reported for their ability to form strong electrostatic interaction
with DNA [13] and used as nucleic acid transporting agents. For example, Kralova
et al. reported that cationic porphyrin derivatives were efficient in transporting
antisense oligodeoxyribonucleotides (ODNs) to primary leukemia cells [14].
Therefore, the electronic interaction with nucleic acids [15] and fluorescence
properties has made porphyrins become promising delivery agents in gene therapy
[16].
Gene therapy has been developed extensively as it provides a unique
approach in treating both inherited and acquired disease. It involves the process of
transferring genetic materials (DNA or RNA) into human cells to replace, correct or
modify a mutated gene. To date, gene therapy has been shown as a successful tool to
cure diseases such as, cystic fibrosis [17-18], severe combined immune deficiency
(SCID) [19], haemophilia [20-21] and muscular dystrophies [22] as well as
Parkinson disease [23]. Gene transfection process requires to surpass several barriers,
starting from repulsion of negatively charged DNA by the negatively charged cell
membrane, enzyme degradation of the DNA trafficks into endosome and finally
internalization of the DNA through the nuclear pore into nucleus (Figure 1.2) [24].
Therefore, the gene delivery process has imposed formidable challenge to the





Figure 1.2 Gene therapy [24]
Retroviruses and adenoviruses have been used as viral vectors in gene
therapy that may present higher gene transfection efficiency compared to their non-
viral counterparts. However, viral vectors may trigger specific immune response and
under certain circumstance could result in death. Their clinical trials indicated
several concerns, such as mutagenesis [24], inflammatory properties [25] and high
cost [22]. On the other hand, cationic polymers such as, polyethylenimine (PEI),
poly-L-lysine, cationic dendrimers and hydrophobic polymers such as poly(lactide-
co-glycolide) (PLG) or polyanhydrides that form polyplexes with DNA are one of
the primary non-viral vectors systems that have been examined for the optimization
of gene delivery [26]. These cationic polymers give protection to DNA from
deoxyribonuclease (DNases) degradation as well as enhancing the intracellular
uptake [27]. However, the clinical trials of these non-viral delivery vectors are
limited by the issues of transfection efficiency, biocompatibility [28], toxicity [29],
low targeting specificity, cellular uptake and tend to aggregate in the blood [24].
These drawbacks have stimulated the search for non-viral gene carriers with
high biocompability and cellular uptake but give low aggregation and minimal safety
concern. In this study, various cationic porphyrin derivatives were synthesized and
their cytotoxicity and intracellular uptake were tested as an evaluation for their























The success of gene therapy largely relies on the ability of gene delivery
vectors to deliver nucleic acid into the targeted cells with minimal toxicity [25, 30].
About 70% of current gene therapies are using the viral method as the main gene-
therapeutic protocols [27], but it is plagued by some serious health issues as well as
inflammatory response [25]. On the other hand, non-viral vectors present the issue
of toxicity [29], low biocompatibility [28], low cellular uptake as well as tend to
aggregate in blood [24].
Porphyrins are interesting alternative to viral vector-mediated gene delivery.
As they are essential compounds in most natural products, such as haemoglobin,
porphyrins probably have higher biocompatibility with human body cells and thereby,
avoiding immune response as induced by viral vectors. Besides, both hydrophilic
and hydrophobic substituents can be directly anchored on the porphyrins macrocycle
to increase their cell membrane penetration, which in turn, increase their cellular
uptake. Whereas, most non-viral vectors require the incorporation of natural lipid
molecules for exogenous DNA transportation into the cell through a biomimetic
mechanism [29]. As highly hydrophobic substituents may cause extensive self-
aggregation in aqueous solution [15], a shorter length of hydrocarbon such as,
butanal and heptanal were employed as hydrophobic substituents in this study.
Besides, porphyrin molecules can strongly fluorescent which favor the
location identification of vectors in the intracellular domain [16]. On the contrary, a
fluorescent probe is required to attach on most other non-viral vectors’ surfaces for
the delivery process tracking. The introduction of the fluorescent probe may
interrupt the physical or chemical properties of the gene vectors, giving an adverse
effect on the biocompatibility and transfection efficiency [28].
In addition, there are abundant of chemical substituents can be covalently
bonded to porphyrin macrocylces for particular nucleic acid or cell-type application




transfectionthrough a “proton sponge” mechanism can be conjugated with porphyrin
to form a complex that may enhance transfection level with minimal toxicity effect.
In this study, various cationic porphyrin derivatives with different number,
location and distribution of lipophilic and hydrophilic ligands along the peripheral of
the macrocycle were synthesized using condensation method and low cost reagents.
To evaluate their potential as gene carriers with minimal toxicity effect, their
cyctotoxicity and cellular uptake studies were conducted.
1.3 Objectives of the Study
The objectives of this study are:
1. To prepare and characterize basic cationic porphyrins.
2. To synthesis and characterize amphiphilic cationic porphyrin derivatives.
3. To synthesis and characterize cationic PAMAM-porphyrin conjugate.
4. To evaluate the cytotoxicity and cellular uptake of the cationic porphyrins
as potential gene delivering reagents.
1.4 Scope of the Study
Condensation method was mainly employed in this study to synthesize
diverse type of porphyrins. All cationic porphyrins were prepared using both
methyl-p-toluenesulfonate and methyl iodide as the alkylation agents. Basic cationic
porphyrin anchored with four cationic groups was synthesized. Besides, amphiphilic
cationic porphyrins bearing different number of hydrophobic and hydrophilic
substituents along the peripheral were also prepared in order to facilitate the
penetration of gene carriers through the cell membrane. Polyamidoamine (PAMAM)
dendrimer was also conjugated to porphyrins to produce a complex with improved




Cytotoxicityof the synthesized compounds towards the cells were conducted
using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay.
The assay was based on cleavage of yellow tetrazolium salt MTT to purple formazan
by the metabolic active cells. In addition, cellular uptakes of the synthetic
porphyrins were investigated in Chinese hamster ovary cells (CHO) and the
qualitative results were obtained using inverted fluorescence microscope.
1.5 Significance of the Study
Porphyrins, as gene delivery agents may have a higher biocompability with
human body cells as they are essential compounds in haemoglobin, thereby avoiding
safety issue as triggered by viral vectors. Synthesis of amphiphilic cationic
porphyrins give a better cell membrane permeability [33], which in turn producing a
better cellular uptake. Self-aggregation is prevented when a shorter length of
hydrocarbons were utilized as hydrophobic groups. Cationic PAMAM-porphyrin
conjugate was also synthesized to enhance transfection level with minimal toxicity
effect. In addition, the fluorescence properties of porphyrins contribute to the use of
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